Gotsch Francesca, Romero Roberto, Friel Lara, Kusanovic Juan Pedro, Espinoza Jimmy, Erez Offer, Than Nandor Gabor, Mittal Pooja, Edwin Samuel, Yoon Bo Hyun, Kim Chong Jai, Mazaki-Tovi Shali, Chaiworapongsa Tinnakorn, Hassan Sonia S
Perinatology Research Branch, NICHD/NIH/DHHS, Bethesda, Maryland, USA.
J Matern Fetal Neonatal Med. 2007 Nov;20(11):777-92. doi: 10.1080/14767050701483298.
Interferon (IFN)-gamma inducible protein, CXCL10/IP-10, is a member of the CXC chemokine family with pro-inflammatory and anti-angiogenic properties. This chemokine has been proposed to be a key link between inflammation and angiogenesis. The aim of this study was to determine whether preeclampsia and delivery of a small for gestational age (SGA) neonate are associated with changes in maternal serum concentration of CXCL10/IP-10.
This cross-sectional study included patients in the following groups: (1) non-pregnant women (N = 49); (2) women with normal pregnancies (N = 89); (3) patients with preeclampsia (N = 100); and (4) patients who delivered an SGA neonate (N = 78). SGA was defined as birth weight below the 10th percentile. Maternal serum concentrations of CXCL10/IP-10 were measured by sensitive immunoassay. Non-parametric statistics were used for analysis.
(1) Patients with normal pregnancies had a significantly higher median serum concentration of CXCL10/IP-10 than non-pregnant women (median 116.1 pg/mL, range 40.7-1314.3 vs. median 90.3 pg/mL, range 49.2-214.7, respectively; p = 0.002); (2) no significant correlation was found between maternal serum concentration of CXCL10/IP-10 and gestational age (between 19 and 38 weeks); (3) there were no differences in median serum CXCL10/IP-10 concentrations between patients who delivered an SGA neonate and those with normal pregnancies (median 122.4 pg/mL, range 37.3-693.5 vs. median 116.1 pg/mL, range 40.7-1314.3, respectively; p > 0.05); (4) patients with preeclampsia had a higher median serum concentration of CXCL10/IP-10 than normal pregnant women (median 156.4 pg/mL, range 47.4-645.9 vs. median 116.1 pg/mL, range 40.7-1314.3, respectively; p < 0.05); (5) patients with preeclampsia had a higher median concentration of CXCL10/IP-10 than those who delivered an SGA neonate (median 156.4 pg/mL, range 47.4-645.9 vs. median 122.4 pg/mL, range 37.3-693.5, respectively; p < 0.05).
Patients with preeclampsia have significantly higher serum concentrations of CXCL10/IP-10 than both normal pregnant women and mothers who have SGA neonates. These results are likely to reflect an anti-angiogenic state as well as an enhanced systemic inflammatory response in patients with preeclampsia. Alternatively, since preeclampsia and SGA share several mechanisms of disease, it is possible that a higher concentration of this chemokine may contribute to the clinical presentation of preeclampsia in patients with a similar intrauterine insult.
干扰素(IFN)-γ诱导蛋白CXCL10/IP-10是CXC趋化因子家族的一员,具有促炎和抗血管生成特性。这种趋化因子被认为是炎症与血管生成之间的关键联系。本研究的目的是确定子痫前期和小于胎龄(SGA)新生儿的分娩是否与母体血清中CXCL10/IP-10浓度的变化有关。
这项横断面研究纳入了以下几组患者:(1)非孕妇(N = 49);(2)正常妊娠妇女(N = 89);(3)子痫前期患者(N = 100);(4)分娩SGA新生儿的患者(N = 78)。SGA定义为出生体重低于第10百分位数。采用灵敏免疫分析法检测母体血清中CXCL10/IP-10的浓度。采用非参数统计进行分析。
(1)正常妊娠患者血清CXCL10/IP-10的中位数浓度显著高于非孕妇(分别为中位数116.1 pg/mL,范围40.7 - 1314.3 vs.中位数90.3 pg/mL,范围49.2 - 214.7;p = 0.002);(2)母体血清CXCL10/IP-10浓度与孕周(19至38周之间)无显著相关性;(3)分娩SGA新生儿的患者与正常妊娠患者血清CXCL10/IP-10的中位数浓度无差异(分别为中位数122.4 pg/mL,范围37.3 - 693.5 vs.中位数116.1 pg/mL,范围40.7 - 1314.3;p > 0.05);(4)子痫前期患者血清CXCL10/IP-10的中位数浓度高于正常妊娠妇女(分别为中位数156.4 pg/mL,范围47.4 - 645.9 vs.中位数116.1 pg/mL,范围40.7 - 1314.3;p < 0.05);(5)子痫前期患者CXCL10/IP-10的中位数浓度高于分娩SGA新生儿的患者(分别为中位数156.4 pg/mL,范围47.4 - 645.9 vs.中位数122.4 pg/mL,范围37.3 - 693.5;p < 0.05)。
子痫前期患者血清CXCL10/IP-10浓度显著高于正常妊娠妇女和分娩SGA新生儿的母亲。这些结果可能反映了子痫前期患者的抗血管生成状态以及全身炎症反应增强。或者,由于子痫前期和SGA有几种共同的发病机制,这种趋化因子浓度较高可能导致类似宫内损伤患者出现子痫前期的临床表现。